🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Congratulations to jehannazri for completing her Master's thesis on investigating #HDAC inhibitors in #psoriasis models with Dr. Vinod Chandran University Health Network and our lab! Wishing her all the best for the future!

Congrats to another superstar in our lab, Dr. Aaron Cabral, for successfully defending his thesis on detecting proximal phosphorylation & covalent modification of proteins! Aaron is now building his pharma business skillset as the Business Development Manager at Dalriada Drug Discovery!

We will be featuring these exceptional trainees throughout the month of September on our Twitter and LinkedIn accounts. Stay tuned! In the meantime, give our Fellows a follow: Emily Gilbert Nila Wu Tudor Radu Wendy Xueyi Wang Zhen Qin

Today is World Duchenne Awareness Day. Coincidentally, it's also my first day of classes in the @TranslationalRP at University of Toronto. I'm very excited to be going back to school - somewhat of a new feeling for me :) - and just as eager to apply what I'll learn to the fight to.. 1/2

First day of 20th grade wooooo! #UofTBackToSchool #PhDFirstYear #chemtwitter

Huge congrats to University Professor Shana Kelley on her appointment as a Fellow to the Royal Society of Canada (RSC // SRC) 🥳 #ImPharmacy Read the full story ⬇️ ⬇️ pharmacy.utoronto.ca/news-announcem…

Tudor Radu is a PhD student with Gunning Group and Scott Prosser. He is working to find a novel, allosteric selective, first-in-class DNAJ-PRKACA inhibitor to treat fibrolamellar hepatocellular carcinoma. U of T Arts & Science #drugdiscovery #cancer (9/11) youtu.be/gj-Crx1qr10

Thanks PRiME - Precision Medicine Initiative at UofT for giving our PhD student Tudor Radu the opportunity to share his research on the development of selective allosteric inhibitors of the oncogenic fusion kinase DNAJ-PRKACA to treat fibrolamellar hepatocellular carcinoma. UTM CPS U of T Mississauga U of T Arts & Science

We are proud to announce the winner of Sweet Biopharma Day 2021. Congratulations to Nabanita Nawar from HDAX Therapeutics for your great presentation! HDAX receives $2500 and memberships to BIOQuébec and BIOTECanada

Wishing all the best to our group's newest Master's graduate,  Merna Hekmat! Merna's research focused on developing a novel class of #covalent kinase inhibitors as treatments for haematological cancers. Catch her on the #medchem job market as she pursues a career in industry!

Congrats to all the HealthInnovationHub Pitch Perfect winners, and a special congrats to our own HDAX Therapeutics!! You're on a roll! 🙌

Happy to share our latest #openaccess collaboration with the JAKSTAT-Target Consortium ERA-Net PerMed in the Journal of Cellular and Molecular Medicine: an integrative cancer interactome analysis of the #JAKSTAT core cancer pathway! onlinelibrary.wiley.com/doi/10.1111/jc…

HealthInnovationHub's FemSTEM 2022 Pitch Competition is happening on March 24th from 3-5 PM! We're thrilled to have not one, but TWO of our incredible PhD students Rebecca Allan, PhD and Nabanita Nawar, PhD in the finals for their respective ventures SciVance and HDAX Therapeutics! h2i.utoronto.ca/2022/03/10/mee…

My first publication is out, a chapter on molecular glue degraders! 😍 It was a lot of fun condensing this amazing field into a cohesive narrative, and I learned so much about degradation pharmacology along the way! #firstpaper

Associate prof, Tenured prof, Assistant prof, emeritus prof

The Centre for Medicinal Chemistry U of T Mississauga is growing into an international research hub for #drugdiscovery in #Ontario! Read more in the Perspective #Mississauga special feature inside the The Globe and Mail! ➡️ perspective.ca/u-of-t-mississ… #business #innovation #entrepreneurship